Shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) have been assigned an average broker rating score of 1.67 (Buy) from the three analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have given a strong buy rating to the company. DelMar Pharmaceuticals’ rating score has declined by 11.3% from 90 days ago as a result of a number of analysts’ ratings changes.
Analysts have set a 1-year consensus price target of $9.95 for the company and are anticipating that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also given DelMar Pharmaceuticals an industry rank of 156 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright set a $12.00 target price on shares of DelMar Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 29th.
Large investors have recently made changes to their positions in the business. Susquehanna International Group LLP acquired a new stake in DelMar Pharmaceuticals during the 3rd quarter valued at $306,000. Sabby Management LLC acquired a new stake in DelMar Pharmaceuticals during the 2nd quarter valued at $1,484,000. Finally, Franklin Resources Inc. acquired a new stake in DelMar Pharmaceuticals during the 2nd quarter valued at $2,477,000. 16.91% of the stock is currently owned by institutional investors.
Shares of DelMar Pharmaceuticals (NASDAQ DMPI) traded down $0.02 during trading hours on Monday, hitting $1.57. The stock had a trading volume of 334,500 shares, compared to its average volume of 1,824,089. DelMar Pharmaceuticals has a one year low of $0.78 and a one year high of $5.39. The firm has a market cap of $33.91, a P/E ratio of -2.31 and a beta of 1,227.20.
DelMar Pharmaceuticals (NASDAQ:DMPI) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). analysts anticipate that DelMar Pharmaceuticals will post -0.54 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://weekherald.com/2018/01/15/zacks-delmar-pharmaceuticals-inc-dmpi-given-consensus-rating-of-buy-by-brokerages.html.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.